Overview

A Randomized Study of the Safety and Efficacy of FG-2216 in Subjects With Renal Anemia Not Requiring Dialysis and Not Receiving Recombinant Human Erythropoietin

Status:
Completed

Trial end date:
2007-07-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to test the safety and efficacy of FG-2216 in the treatment of patients with renal anemia who are not receiving erythropoietin and who are not on dialysis.

Phase:

Phase 2

Details

Lead Sponsor:

FibroGen

Treatments:

Epoetin Alfa